Ogden Christopher Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
5
Insider Sells Sum
$17,525.31

Insider Activity of Ogden Christopher

According to the SEC Form 4 filings, Ogden Christopher, being in a position of

  1. Chief Financial Officer at CytomX Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 20947 shares for $129,065,
    over all time since 2023-03-16, has bought 0 shares, and sold 49214 shares for $179,972.

Biography of Ogden Christopher

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $129,0652100

Comparison of Insiders on Amount of Buys and Sells

2026-06-15SaleCytomX Therapeutics, Inc.
CTMX
Chief Financial Officer
1,624
0.001%
$3.05$4,953+7.24%
2026-03-17SaleCytomX Therapeutics, Inc.
CTMX
Chief Financial Officer
19,323
0.0134%
$6.42$124,112-37.25%
2025-06-16SaleCytomX Therapeutics, Inc.
CTMX
Chief Financial Officer
10,614
0.0074%
$2.69$28,540+54.88%
2025-06-13SaleCytomX Therapeutics, Inc.
CTMX
Chief Financial Officer
1,641
0.0011%
$2.95$4,841+39.45%
2025-03-18SaleCytomX Therapeutics, Inc.
CTMX
Chief Financial Officer
8,551
0.0106%
$0.60$5,122+338.96%
2024-08-20SaleCytomX Therapeutics, Inc.
CTMX
Chief Financial Officer
1,984
0.0025%
$1.23$2,439-10.08%
2024-03-19SaleCytomX Therapeutics, Inc.
CTMX
SVP, Finance and Accounting
2,971
0.0042%
$2.09$6,196-45.64%
2023-12-20SaleCytomX Therapeutics, Inc.
CTMX
SVP, Finance and Accounting
1,990
0.0031%
$1.38$2,747+5.6%
2023-03-16SaleCytomX Therapeutics, Inc.
CTMX
SVP, Finance and Accounting
516
0.0008%
$1.98$1,021-20.62%
Total: 9
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.